ASNC has confirmed reports that supply disruptions with both Tc-99m pyrophosphate (PYP) and Tc-99m hydroxymethylene diphosphonate (HMDP or HDP) may take place after January 2026. These products are used in the diagnosis of cardiac amyloidosis.
ASNC is in contact with the manufacturers of both products to understand the extent of the shortages and the projected timelines for resuming production.
ASNC will share updates as this issue evolves. To be among the first to receive email alerts with breaking news, be sure to keep your ASNC membership current.
Article Type
News & Announcements
Category
Advocacy
Related Posts
Watch This Interview! ASNC President Details Health Policy Priorities
Following ASNC’s May 5 Capitol Hill Day, Jamieson Bourque, MD, MHS, FASNC,…
ASNC on Capitol Hill: ‘We Are Here in the Name of Patient Access to Care,’ Says ASNC President
On May 5, ASNC hosted its annual congressional briefing, where Society leaders…
Radiopharmaceuticals Expert Joins Lineup for ASNC’s May 5 Congressional Briefing on Improving Access to Cardiac Imaging
Etienne Montagut, president and CEO of PharmaLogic, will present at ASNC’s upcoming…


